INTRAHEALTH LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +8.3%

  £29,531,918 → £31,987,745

• Cash

  -10.2%

  £2,243,560 → £2,014,473

• Net assets

  +18.4%

  £2,282,410 → £2,702,974

• Employees

  +9.6%

  697 → 764

• Operating profit

  +26.2%

  £709,773 → £895,994

• Profit before tax

  +36.8%

  £524,435 → £717,426

• Wages

  +13.5%

  £14,792,975 → £16,796,924

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. INTRAHEALTH LIMITED 2003-02-24 → present
2. GREG MOORHOUSE CLINICAL PRESCRIBING CONSULTANCY LIMITED 1999-08-13 → 2003-02-24
3. DOVEGLADE LIMITED 1999-06-07 → 1999-08-13

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

UNW LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The directors have a reasonable expectation that the company has adequate financial and other resources to continue in operational existence for the foreseeable future. Accordingly, they continue to prepare the financial statements on a going concern basis.”

Group structure

1. INTRAHEALTH LIMITED · parent
   1. IntraHealth Pharmacy Limited 100% · United Kingdom
   2. Landtime Limited 100% · United Kingdom

Significant events

• “The year 2024/25 showed a continued growth in profitability for the group. While margins remain tight in all areas of the business, tight fiscal control and revenue growth continues to drive this.”
• “During the year our revenue grew by 8.3%, to £32m, whilst cost of sales grew by 8.1% to £25m maintaining a gross profit margin of 21%, consistent with previous years' results.”
• “Administrative expenses have grown by 4.6%. Combined with the above this has increased the operating profit by 26.2% to £0.9m.”
• “We operate ten NHS general practices in the North East of England. The combined list of 65,699 (2024: 64,997) at end of year is an increase of 1.1%.”
• “We continued action to reduce locum spend resulting in a decrease of £712k in 2024/25, to its lowest level since 2021/22.”
• “In April 2024, we commenced delivery of the Tees Valley Anticoagulation Monitoring service, greatly increasing our reach in this area.”
• “Also in April 2025, we mobilised our newly retained and expanded immunisation service in Greater Manchester to an Integrated Vaccination and Immunisation Service (IVIS) delivering services to predominantly school aged children. We had previously delivered only the flu element of this service.”
• “We have also been successful in winning Cheshire School Aged Immunisation Services (SAIS) contract which will be mobilised to commence in September 2025.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.